"The Report
PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Description
PharmaPoint: Rheumatoid
Arthritis - 5EU Drug Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints. It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
The key drivers of this growth
include an increase in the RA patient population, higher drug prices
in Germany as compared with the other four major EU countries, and
ample opportunities within the biosimilars market. However, the
Italian government is implementing austerity measures to keep
healthcare costs low, and is expected to promote the use of less
expensive treatment alternatives. However, the growth of the RA
market in Spain will be hindered by the implementation of austerity
measures, which aim to cut healthcare costs and will thus limit the
prescribing of biologic agents. The key drivers of this growth
include the increasing RA patient population and the universal
healthcare system, which allows all RA patients access to healthcare,
while austerity measures aimed at cutting healthcare costs will serve
as a barrier to market growth.
View Full Report at
http://www.marketresearchreports.biz/analysis/247059
Scope
- Overview of Rheumatoid
arthritis including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on the
key drugs in the 5EU including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in the 5EU from 2013-2023.
- Analysis of the impact of
key events as well the drivers and restraints affecting the 5EU
Rheumatoid arthritis market.
Download
Detail Report With Complete TOC at
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid arthritis
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in the 5EU.
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment